Investor Announcements - 2011

EKF wins IMSS contract

30^th Nov 2011

EKF Diagnostics has been awarded a contract in Mexico for 3,500 HemoPoint H2 haemoglobin testing devices.

Announcement of Interim Results

28^th Sep 2011

EKF Diagnostics Holdings plc announces its unaudited interim results for the six month period ended 30 June 2011, a period of transition, investment and progression.

Distribution agreement with Alere

23^rd May 2011

EKF Diagnostics announces that it has entered into a conditional distribution agreement with Alere Inc.

EKF announces acquisition of Stanbio Laboratory

23^rd May 2011

Proposed acquisition of the entire issued share capital of Stanbio Laboratory L.P.

Quotient Diagnostics receives SFDA approval

27^th Jan 2011

Quotient Diagnostics has received approval from China’s SFDA for its Quo-Test A1C test.

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

MEDLAB Dubai - Feb 2020

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities

Medica 2019

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.